Allogene's off-the-shelf CAR-T cells produce responses in patients

Allogene's off-the-shelf CAR-T cells produce responses in patients

STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

By ADAM FEUERSTEIN

WELLCOME COLLECTION

The company released updated results from the first study of its off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma.

READ MORE